<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03742544</url>
  </required_header>
  <id_info>
    <org_study_id>ID-TERO-401</org_study_id>
    <nct_id>NCT03742544</nct_id>
  </id_info>
  <brief_title>Post Marketing Surveillance of Telostop TAB (Telmisartan/Rosuvastatin) for Evaluating the Safety and Efficacy</brief_title>
  <official_title>Post Marketing Surveillance of Telostop TAB (Telmisartan/Rosuvastatin) for Evaluating the Safety and Efficacy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>IlDong Pharmaceutical Co Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>IlDong Pharmaceutical Co Ltd</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Post-marketing surveillance of Telostop TAB (Telmisartan/Rosuvastatin)
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Telostop TAB is fixed-dose combination of telmisartan and rosuvastatin, which was approved in
      2015 in the Republic of Korea for the treatment of patients with hypertention and
      dyslipidemia. A post-marketing surveillance was conducted following the approval to obtain
      data on the safety and efficacy of Telostop TAB in real-world practice.
    </textblock>
  </detailed_description>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Actual">June 23, 2015</start_date>
  <completion_date type="Anticipated">October 30, 2020</completion_date>
  <primary_completion_date type="Anticipated">October 30, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of adverse event after this drug administration in general medical practice</measure>
    <time_frame>24 weeks</time_frame>
    <description>Any adverse events occurred after this drug dosing will be recorded. Description of adverse event(s) including type of adverse event(s), onset/end date, severity, action taken, causal relationship to the drug and investigator's view on the adverse event(s) will be captured, whether it is related to the drug or not and until follow up visit more than 1 time during the surveillance period.
Lab abnormalities and changes in vital signs are considered to be adverse events only if they result in discontinuation from the study, necessitate therapeutic medical intervention, and/or if the investigator considers them to be adverse events.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The change from baseline to week 24 in the LDL cholesterol</measure>
    <time_frame>24 weeks</time_frame>
    <description>LDL cholesterol is measured before administration of the drug and within 24 weeks after administration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The change from baseline to week 24 in the blood pressure</measure>
    <time_frame>24 weeks</time_frame>
    <description>Blood pressure is measured before administration of the drug and within 24 weeks after administration.</description>
  </secondary_outcome>
  <enrollment type="Anticipated">600</enrollment>
  <condition>Hypertension</condition>
  <condition>Dyslipidemias</condition>
  <eligibility>
    <study_pop>
      <textblock>
        residents of Korea, in real-world practice
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  The patient who is first prescribed and administered Telostop plus Tab.

        Exclusion Criteria:

          -  The patients who are overreacting to this drug or its components

          -  The patients to the &quot;Do not administer to the next patient&quot; section of the approved
             instructions for use
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>November 2018</verification_date>
  <study_first_submitted>November 12, 2018</study_first_submitted>
  <study_first_submitted_qc>November 14, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">November 15, 2018</study_first_posted>
  <last_update_submitted>November 14, 2018</last_update_submitted>
  <last_update_submitted_qc>November 14, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">November 15, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dyslipidemias</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

